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ABSTRACT
Background: For the first time in Korea, we aimed to study the efficacy and safety of cannabidiol 
(CBD), which is emerging as a new alternative in treating epileptic encephalopathies.
Methods: This study was conducted retrospectively with patients between the ages of 
2–18 years diagnosed with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) were 
enrolled from March to October 2019, who visited outpatient unit at 3 and 6 months to 
evaluate medication efficacy and safety based on caregiver reporting. Additional evaluations, 
such as electroencephalogram and blood tests, were conducted at each period also. CBD was 
administered orally at a starting dose of 5 mg/kg/day, and was maintained at 10 mg/kg/day.
Results: We analyzed 34 patients in the LGS group and 10 patients in the DS group between 
the ages of 1.2–15.8 years. In the 3-month evaluation, the overall reduction of seizure 
frequency in the LGS group was 52.9% (>50% reduction in 32.3% of the cases), and 29.4% 
in the 6-month evaluation (more than 50% reduction in 20.6%). In DS group, the reduction 
of seizure frequency by more than 50% was 30% and 20% in the 3-month and 6-month 
evaluation, respectively. Good outcomes were defined as the reduction of seizure frequency 
by more than 50% and similar results were observed in both LGS and DS groups. Adverse 
events were reported in 36.3% of total patients of which most common adverse events were 
gastrointestinal problems. However, no life-threatening adverse event was reported in both 
LGS and DS during the observation period.
Conclusion: In this first Korean study, CBD was safe and tolerable for use and could be 
expected to potentially reduce the seizure frequency in pediatric patients with LGS or DS.
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INTRODUCTION
Epilepsy is associated with cognitive dysfunction and behavioral disorders. Uncontrolled seizures 
often affect one's quality of life, especially when they occur at a young age.1-5 In particular, in 
epileptic encephalopathies such as Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), 
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epileptic activity causes severe cognitive and behavioral disorders to worsen over time.6
Purified cannabidiol (CBD) (Epidiolex®; GW Pharmaceuticals, Cambridge, UK) is a new drug 
that can be used to treat drug-resistant epilepsy,7 as its administration can reduce seizure 
frequency. Mild adverse events such as somnolence and gastrointestinal (GI) symptoms have 
been reported.7-10 After randomized trials assessing CBD use in LGS and DS were conducted, 
the United States Food and Drug Administration approved the prescription of CBD for both 
epileptic encephalopathies in 2018.11,12
CBD exerts anti-seizure effects, while another component of cannabis, Δ9-tetrahydrocannabinol 
(THC), has psychoactive functions.13,14 In Korea, due to the addictive nature of THC, even CBD 
was considered an illegal drug until March 2019. The efforts of the media, patient groups, and 
non-governmental organizations informed the public that CBD medication contained a very 
small amount of THC, with a very low potential for addiction and psychoactive effects. These acts 
led to the approval of CBD by the Ministry of Food and Drug Safety for the treatment of DS or 
LGS in those over two years of age.
This study was performed to evaluate the tolerability and efficacy of CBD in children with 
LGS or DS for the first time in Korea.
METHODS
Patients and study design
Patients who initiated CBD treatment from March 2019 to October 2019 and who were 
between the ages of 2 and 18 years and diagnosed with of DS or LGS were included in this 
study. All patients diagnosed with DS met the clinical diagnostic criteria, including an 
early onset of febrile or vaccination related seizures, developmental regression in relation 
to the seizures, and drug-resistant epilepsy. All had pathogenic SCN1A (sodium channel, 
voltage-gated, type I, alpha subunit) mutations. All patients diagnosed with LGS exhibited 
impaired intellectual function and multiple mixed-type seizures, as well as characteristic 
electroencephalography (EEG) patterns showing generalized sharp and slow waves (GSSW) 
or generalized paroxysmal fast activities (PFA). This study was conducted retrospectively 
and evaluated the medication efficacy and safety through outpatient visits at 3 and 6 
months based on caregiver reporting. Patients received Epidiolex®, manufactured by GW 
Pharmaceuticals, which contained CBD (100 mg/mL). CBD was administered orally at a 
starting dose of 5 mg/kg/day, in addition to baseline antiepileptic drug therapy. After 1 week, 
the dosage was up-titrated by 5 mg/kg/day and was maintained at 10 mg/kg/day (Fig. 1).
Assessment of efficacy
The efficacy of CBD was evaluated by comparing the mean frequency of motor seizures 
experienced per month, defined by the tonic, clonic, and atonic components, before and 
after the administration of medication. The change in the seizure frequency was expressed 
as a percentage that was calculated as [(seizure frequency per month) − (seizure frequency 
at baseline)]/(seizure frequency at baseline) × 100. Each patient's response to CBD was 
categorized as one of the following 4 responses: 1) the patient became seizure-free, 2) the 
frequency of seizures was reduced by more than 50%, 3) the frequency of seizures was 
reduced by less than 50%, or 4) there was no effect. A good outcome was defined as the 
seizure frequency being reduced by more than 50%, including being seizure-free.
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The additional effect of CBD was evaluated based on comparisons of the EEGs performed during 
each period, and each assessment was performed for 30 minutes or more. Each scalp electrode 
was placed in accordance with an international 10–20 system. The diagnosis was based on the 
characteristic interictal and ictal patterns of the EEG.15 In the LGS group, we evaluated whether 
the EEG improved at the 3- and 6-month visits, and the criteria were based on the persistence of 
the EEG characteristics of LGS or the prevalence of the epileptiform pattern.16
Assessment of safety
All safety results in this report were evaluated over the entire follow-up period. Patients 
or caregivers documented the adverse events at each visit. Safety was assessed through 
laboratory studies, including complete blood counts, liver function tests, and vital signs at 
baseline and at the time of the outpatient clinic visits. The appearance of adverse events was 
resolved by dose reduction or discontinuation of treatment.
Analyses
An intention-to-treat analysis was conducted to assess CBD efficacy. Data processing and 
analysis were performed with Statistical Package for the Social Sciences version 25 (IBM Co., 
Armonk, NY, USA). P values < 0.05 were regarded as statistically significant. All numbers were 
rounded to 2 decimal places. The statistical analyses included the independent paired-sample 
t-test and Fisher's exact test, and Pearson's χ2 test to compare the variables and prognosis.
Ethics statement
This study was approved by the Institutional Review Board of Severance Hospital (approval 
No.: 4-2020-0120). Informed consent was waived due to the retrospective nature of the study.
RESULTS
Study population
During the study period, 44 patients were managed with CBD, 34 of whom were in the LGS 
group and 10 of whom were in the DS group. One patient from the LGS group was excluded 
due to follow-up loss. One patient from the DS group was excluded due to the occurrence of 
an adverse event before the 3-month evaluation. After the 3-month evaluation, 6 patients in 
the LGS group were excluded from the study due to dissatisfaction with the treatment effect, 
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Fig. 1. Cannabidiol schedule. 
CBD = cannabidiol, EEG = electroencephalogram.
and 3 patients were excluded because of the development of adverse events. In the DS group, 
1 patient was excluded due to adverse events and 2 were excluded due to financial constraints 
(Fig. 2).
The ages of the patients included in this study ranged from 1.2 to 15.8 years (mean age = 
5.1 years), with 28 males (63.6%) and 16 females (36.4%). There were 5 patients (11.4%) 
undergoing diet therapy. The most frequently used antiepileptic drug at the time of the study 
was valproic acid (VPA) at an average dose of 22.2 mg/kg/day, followed by levetiracetam 
at an average dose of 20.3 mg/kg/day. Stiripentol was used only in DS patients. Patient 
characteristics are shown in Table 1.
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Total enrolled
(n = 44)
1 patient stop due to side effect1 patient follow-up loss
2 patients stop due to cost problem
1 patient stop due to side effect
8 patients stop due to dissatisfaction
with the effect




LGS (n = 33)
6-month evaluation




DS (n = 9)
6-month evaluation
DS (n = 6)
Fig. 2. Study participants' flow chart. 
LGS = Lennox-Gastaut syndrome, DS = Dravet syndrome.
Table 1. Baseline characteristics
Characteristics Patients receiving CBD (n = 44)
Male:female 28 (63.6):16 (36.4)
Mean age, yr 5.1 (max = 15.8, min = 1.2, IQR = 2.9–6.5)
Epilepsy syndrome
Lennox-Gastaut syndrome 34 (77.3)
Dravet syndrome 10 (23.3)
Concomitant use of antiepileptic drugs 3 (1–5)
Antiepileptic drugs used




Other treatment in progress at the time of CBD use
Diet therapya 5 (11.4)
Steroidsb 2 (4.5)
EEG patterns before cannabidiol treatment
Paroxysmal fast activities 16 (36.3)
Generalized sharp and slow waves 17 (38.6)
Abnormal brain MRI findings 22 (50)
Data are presented as median (range) or number (%) unless otherwise indicated.
CBD = cannabidiol, IQR = interquartile range, EEG = electroencephalogram, MRI = magnetic resonance imaging.
aAll diet therapies used in this study were the modified Atkins diet; bAll used deflazacort.
Efficacy in LGS
When outcomes were observed in the LGS group, a reduction in seizure frequency was 
observed in 52.9% of the patients at 3 months and in 29.4% at 6 months. Eight patients 
(23.5%) were seizure-free at the 3-month evaluation, 3 patients (8.8%) had a reduction in 
seizure frequency of more than 50%, and 7 patients (20.6%) showed a reduction in seizure 
frequency of less than 50%. It can be stated that the result was good in 32.3% of patients. At 
the 6-month evaluation, 4 patients (11.8%) were seizure-free and 3 patients (8.8%) showed 
more than a 50% reduction in seizure frequency; thus, 20.6% of the patients had good 
outcomes (Fig. 3A).
When evaluating the initial EEGs of LGS patients, 16 cases showed GSSW or PFA, 
characteristic of LGS. The outcomes at the 3- and 6-month evaluations were investigated. 
At the 3-month evaluation, good outcomes were observed as there were more cases with 
an initial EEG that did not show the PFA, but at the 6-month evaluation, the opposite was 
observed. In the case of the GSSW pattern, good outcomes were obtained, with no cases 
showing the pattern at either the 3- or the 6-month evaluations; however, there was no 
statistically significant change in EEG activity after the administration of CBD.
When compared with the baseline EEG, most of the patients who showed no improvement at 
the 3-month evaluation (P value = 0.017) and the 6-month evaluation (P value = 0.009) were 
determined to have had a “no effect” outcome.
Efficacy in DS
In the DS group, the “no effect” outcome was observed at a higher frequency at both the 3- 
and 6-month evaluations than it was in the LGS group. At the 3-month evaluation, 1 patient 
(10.0%) was seizure-free, 2 patients (20.0%) showed a more than 50% reduction in seizure 
frequency, and 60.0% of the enrolled patients experienced no effect. None of the patients 
were “seizure-free” at the 6-month evaluation, and only 2 (20.0%) showed a reduction in 
seizure frequency of 50% or more. At the 6-month evaluation, a “no effect” outcome was 
observed in 66.7% of patients (Fig. 3B).
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Seizure free Over 50% Under 50% No effect
Fig. 3. Outcome of seizures with cannabidiol treatment. (A) At 3 and 6 months of evaluation in LGS. (B) At 3 and 6 months of evaluation in DS. 
LGS = Lennox-Gastaut syndrome, DS = Dravet syndrome.
Safety
No life-threatening adverse event was reported in the LGS and DS groups during the 
observation period. However, adverse events were reported in 16 (36.3%) of the enrolled 
patients, and GI problems were the most frequent adverse event in 7 cases (15.9%); among 
them, mild liver enzyme elevation was observed in 1 case, whereas most included vomiting 
or diarrhea. Five cases (11.4%) experienced behavioral changes, such as irritability, 
hyperactivity, excessive alertness, and sleep disturbances (Table 2). In the DS group, 2 cases 
had increased seizure frequency, which warranted the discontinuation of the medication. 
The other adverse events necessitating the cessation of the drug were as follows: 1 case of 
drowsiness, 1 case of GI problems with acute pancreatitis, and 1 case of behavioral changes.
DISCUSSION
This study evaluated the efficacy and safety of CBD administration for treating LGS and DS 
for the first time in Korea. A good treatment outcome was observed in 31.8% of patients at 
the 3-month evaluation and in 20.5% at the 6-month evaluation, including both the LGS and 
DS groups. This positive response was lower than the 36%–57% positive response within 6 
months shown previously by studies that did not distinguish between the patient groups.7,8,17
Among the LGS patients, a good outcome was observed in 32.4% of cases at the 3-month 
evaluation and in 20.6% at the 6-month evaluation, which was similar to the percentage of all 
patients who showed good treatment outcomes overall. When comparing the effects of CBD 
treatment over a similar period in other studies that assessed LGS patients, good outcomes 
were noted in 33%–44% of cases.11,18 In our study, the percentage of good outcomes was 
slightly lower; however, it was within a similar range. According to a study by Thiele et al.11 
conducted in 2018, when comparing the LGS group using CBD and a patient group receiving 
a placebo, the monthly frequency of drop attacks decreased by 43.9% in those receiving 
CBD, compared to a reduction of only 21.8% in the placebo group. The total monthly seizure 
frequency decreased by 41.2% in the CBD group compared to a 13.7% decrease in the placebo 
group. Moreover, Thiele et al.11 documented that caregivers reported an improved condition 
in the CBD group that was 24% more than that of the placebo group. From these results, it 
appears that the use of CBD in LGS patients can reduce the frequency of seizures, including 
drop attacks, which can be a major obstacle in everyday life; thus, CBD treatment provides 
the opportunity for a good treatment outcome by reducing the seizure frequency by more 
than 50% in LGS patients.
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Table 2. Adverse events of cannabidiol
Adverse events Values
Gastrointestinal problems 7 (15.9)
Vomiting or diarrhea 4 (9.1)
Decreased appetite 1 (2.3)
Liver enzyme elevation 1 (2.3)
Acute pancreatitis 1 (2.3)
Drowsiness 3 (6.8)
Reduction of AED dosages 2 (4.5)
Reduction of CBD dosage 1 (2.3)
Behavioral changes 5 (11.4)
Increased seizure frequency 2 (4.5)
Skin rash 1 (2.3)
Values are presented as number (%).
AED = antiepileptic drug, CBD = cannabidiol.
In the case of the DS group, as the number of patients enrolled was small, an accurate 
evaluation was difficult. Upon reviewing previous studies, the reduction in seizure frequency 
by more than 50% was found to be about 43%,12,19 whereas, in our research, it was 30.0% 
at the 3-month evaluation. We evaluated the EEG changes and outcomes as we did with the 
LGS, but the changes do not seem to be relevant. Devinsky et al.12 reported that the monthly 
frequency of motor seizures experienced by the DS group using CBD decreased by a median 
of 6.5%, compared to a reduction of 0.8% in the placebo group. However, patients with LGS 
improved not only in terms of motor seizures but also in terms of seizures of other types, 
whereas DS patients showed no significant improvement in seizures overall, except for 
motor seizures.12
According to a recently published study that conducted a comparison of outcomes and CBD 
dosages in a DS patient group, the number of cases experiencing a reduction in seizure 
frequency of at least 50% was higher in the CBD 20 group (20 mg/kg/day) than in the CBD 10 
group (10 mg/kg/day). On the contrary, more individuals experienced a reduction in seizure 
frequency of more than 75% in the CBD 10 group than in the CBD 20 group.19 In a study 
related to LGS treatment with CBD published in 2018, a reduction in the frequency of seizures 
by more than 50% during the research period was observed for 36% of patients in the CBD 10 
group and 39% of patients in the CBD 20 group. Moreover, the median percent reduction in 
monthly seizure frequency tended to decrease further at a higher dosage of CBD, except for 
non-drop attacks.18
Usually, adverse events related to CBD administration are mild, and the most common 
adverse events are drowsiness and GI problems such as diarrhea. In rare cases, serious 
adverse events occur that may require hospital admission for treatment, such as status 
epilepticus or extrapyramidal symptoms.7,8,20 However, in the case of status epilepticus, 
the causal relationship with CBD is unclear because most enrolled patients were those with 
refractory epilepsy, such as LGS or DS. In our study, similar to others, the adverse events 
reported included high rates of GI problems, such as diarrhea and inadequate appetite, which 
can be expected, as the current formulation of CBD in use is in the form of an oil.
Drowsiness and other adverse events, such as elevated liver enzymes, that have been reported 
in some studies7 were thought to be essential for confirming the interaction between CBD 
and antiepileptic drugs such as VPA and clobazam (CLB) through further research; the reason 
for this is that the metabolism of CBD by the liver can inhibit cytochrome P450. This affects 
the metabolism of some antiepileptic drugs; in the case of CLB, it can increase the serum 
level of N-desmethylclobazam, which is an active metabolite of CLB.8,21-24
There were some limitations in this study. For example, this study was performed with 
a small number of enrolled patients from a single institution; primary data collection 
was performed through the assessment of caregivers' reports; and adverse events were 
investigated retrospectively and may not have been accurate. In addition, there may have been 
a selection bias.
However, this study is still meaningful, as it is the first pilot study to be conducted in Korea, 
showing that CBD can be used effectively and safely at a dose of 10 mg/kg/day for treating 
children of Asian ethnicity. In the future, we plan to conduct a well-designed, randomized, 
controlled clinical trial to evaluate CBD efficacy, safety, and drug interactions.
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